This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Peregrine Pharma

Stocks in this article: PPHM ARNA VVUS QCOR HEB

BOSTON ( TheStreet) -- Michael A. opens this week's Biotech Stock Mailbag with a question about Peregine Pharmaceuticals (PPHM):

"Peregrine has come a long way from the 1990s when they were doing just mice along and today they are doing trials on people. They will be going to phase III trials within a few more months. Did you listen to the conference call on July 16? Your thoughts now? I see big things coming from Peregrine."

Peregrine executives are sneaky and two faced. In public, Peregrine CEO Steven King talks enthusiastically about the "exceptional" data from a phase II study of bavituximab in non-small cell lung cancer that has resulted in a "surge" in interest from potential partners.

Privately, however, King has directed the company to sell massive amounts of stock in opaque, back-door financing deals that have diluted shareholders by an astounding 45% in the most recently completed fiscal year, regulatory records show.

Investors should pay more attention to what company executives do, rather than listen to what they say. In Peregrine's case, the company is selling tons of cheap stock on the sly, mostly to uninformed retail investors who are buying it on the belief that company executives are sincere about their stated excitement for bavituximab. Well, if the bavituximab data were so great -- and by inference Peregrine was significantly undervalued -- the company wouldn't stoop to raise money at such low levels.

But yet that's exactly what Peregrine has been doing. In the fiscal year that ended on April 30, Peregrine sold 31.1 million shares of stock. Peregrine's share count as of April 30 was 101.4 million, which means the company diluted shareholders by 45% in the 2012 fiscal year over fiscal 2011, according to regulatory records.

Almost 80% of Peregrine's fiscal 2012 stock sales came through At The Market (ATM) stock offerings. These ATM financing arrangements allow companies, through a broker or investment bank, to sell treasury stock to investors at current market prices. Small companies like ATMs because it's a relatively easy and cheap way to raise cash. But these financing vehicles aren't so great for current shareholders because companies do not have to disclose the sale of stock through ATMs except in customary regulatory filings at the end of each quarter or fiscal year.

Peregrine executives don't talk publicly about the company's ATM sales. In fact, Peregrine does a pretty good job of keeping these stock sales as opaque as possible, burying details in the footnotes of its most recent 10-K filed with the Securities and Exchange Commission.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs